公开(公告)号：US20240360248A1

公开(公告)日：2024-10-31

申请号：US18684078

申请日：2022-08-17

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Chung Lim WONG ,  Hong Hoi TING

IPC: C07K16/40 ,  G01N33/573 ,  G01N33/68

CPC classification number: C07K16/40 ,  G01N33/573 ,  G01N33/6854 ,  C07K2317/565 ,  C07K2317/569

Abstract: Provided are a set of specific single-domain antibody coding sequences targeting PTK7 and an application thereof. The provided anti-PTK7 single-domain antibody may effectively bind to a PTK7 antigen, which provides a basis for the research and development of drugs targeting PTK7, including radionuclide drug conjugates, antibody drug conjugates, multispecific antibody drugs and so on.

公开(公告)号：US20240360205A1

公开(公告)日：2024-10-31

申请号：US18648572

申请日：2024-04-29

Applicant: SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. ,  HyTest Ltd.

Inventor： Vladimir L. Filatov ,  Petr N. Datskevich ,  Antonina S. Kokisheva ,  Alexey G. Katrukha ,  Stanislav V. Kozlovsky ,  Alexander B. Postnikov ,  Fedor N. Rozov ,  Tao TANG ,  Chengxiong ZHAN ,  Lingjia WU ,  Shibo ZHU ,  Ke LI ,  Yue WU

IPC: C07K16/18 ,  G01N33/68

CPC classification number: C07K16/18 ,  G01N33/6854 ,  C07K2317/565

Abstract: The present application relates to a PINP-specific antibody, kit and use thereof. Specifically, the present invention provides a PINP-specific antibody, as well as a kit containing the antibody, and use thereof in detecting the presence or level of tPINP in a sample.

公开(公告)号：US20240358853A1

公开(公告)日：2024-10-31

申请号：US18598746

申请日：2024-03-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In IM ,  Jin Hee BAE ,  Nazarii FRANKIV

IPC: A61K48/00 ,  A61K9/00 ,  A61K38/17 ,  A61P25/24 ,  C12N15/86 ,  G01N33/68

CPC classification number: A61K48/005 ,  A61K9/0019 ,  A61K38/1709 ,  A61P25/24 ,  C12N15/86 ,  G01N33/6854 ,  G01N33/6893 ,  C12N2750/14143

Abstract: According to the present disclosure, the relation between the MeCP2 expression level and depression in D2R neurons of the ventral striatum was first found, and it was confirmed that MeCP2 in D2R neurons of the ventral striatum was significantly decreased due to depressive symptoms, and depressive symptoms were improved when MeCP2 expression in the neurons was up-regulated. Accordingly, the expression level of MeCP2 in D2R neurons of the ventral striatum is provided as a biomarker for diagnosing depression and the up-regulation of the MeCP2 expression is provided as a treatment strategy for depression, and thus, it is expected to be useful as a development platform for drugs for preventing or treating depression in the future.

公开(公告)号：US20240358761A1

公开(公告)日：2024-10-31

申请号：US18682798

申请日：2022-08-11

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER

IPC: A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/00 ,  A61K45/06 ,  C07K14/705 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86 ,  C12N15/90 ,  G01N33/68

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61K45/06 ,  C07K14/70596 ,  C12N9/22 ,  C12N15/111 ,  C12N15/86 ,  C12N15/907 ,  G01N33/6854 ,  A61K2239/25 ,  A61K2239/38 ,  C12N2310/20 ,  C12N2740/15043 ,  G01N2333/70539 ,  G01N2800/24 ,  G01N2800/52

Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells.

公开(公告)号：US20240353423A1

公开(公告)日：2024-10-24

申请号：US18763265

申请日：2024-07-03

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Giane Oliveira Sumner ,  Jihua Chen

IPC: G01N33/68 ,  G01N33/577 ,  G01N33/58 ,  G01N33/94

CPC classification number: G01N33/6854 ,  G01N33/577 ,  G01N33/58 ,  G01N33/94

Abstract: The present disclosure provides methods for mitigating drug target interference in an anti-drug antibody (ADA) immunoassay, wherein the ADA immunoassay comprises one or more target blocking reagents under mild basic pH assay conditions.

公开(公告)号：US20240345090A1

公开(公告)日：2024-10-17

申请号：US18580710

申请日：2022-07-19

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： Malú Mariadelourdes Gámez TANSEY ,  Habibeh KHOSHBOUEI

IPC: G01N33/573 ,  A61K38/00 ,  C07K14/525 ,  G01N33/68

CPC classification number: G01N33/573 ,  C07K14/525 ,  G01N33/6854 ,  A61K38/00 ,  G01N2333/90245 ,  G01N2800/50

Abstract: Disclosed is a method for detecting a level of tyrosine hydroxy lase (TH) in a biosample from a subject. The biosample comprises a homogenate of peripheral monocytes from the subject. Detection involves conducting an ELISA on the biosample using a biotinylated anti-TH antibody under conditions to allow the biotinylated anti-TH antibody to bind to TH. If elevated TH is detected, an amount of a TNFα inhibitor effective to decrease TH in peripheral monocytes of the subject may be administered. In a particular method, a TNFα inhibitor is administered if the TH level in the biosample is higher than a threshold level.

公开(公告)号：US20240343798A1

公开(公告)日：2024-10-17

申请号：US18682489

申请日：2022-08-09

Applicant: GV20 Therapeutics LLC ,  Shanghai XunBaiHui Biotechnology Co., LTD.

Inventor： Tengfei Xiao ,  Xihao Hu ,  Xiaole Shirley Liu

IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/04 ,  G01N33/50 ,  G01N33/574 ,  G01N33/68

CPC classification number: C07K16/2803 ,  A61K45/06 ,  A61P35/04 ,  G01N33/5023 ,  G01N33/57492 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N2333/70503

Abstract: The present invention provides methods and compositions for treating a cancer, and/or an autoimmune disease, by modulating the expression and/or activity of IGSF8 and its binding ligands. The pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind human IGSF8, and have an activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.

公开(公告)号：US12110320B2

公开(公告)日：2024-10-08

申请号：US17698645

申请日：2022-03-18

Applicant: The University of North Carolina at Chapel Hill

Inventor： Samuel Lai ,  M. Gregory Forest ,  Christine Henry ,  Timothy Wessler ,  Alexander Chen ,  Jennifer Schiller ,  Jay Newby

IPC: A61K39/04 ,  A61P31/00 ,  C07K16/08 ,  C07K16/10 ,  C07K16/12 ,  C07K16/44 ,  G01N33/543 ,  G01N33/557 ,  G01N33/569 ,  G01N33/68 ,  A61K38/00

CPC classification number: C07K16/1235 ,  A61P31/00 ,  C07K16/087 ,  C07K16/1045 ,  C07K16/44 ,  G01N33/54346 ,  G01N33/557 ,  G01N33/56983 ,  G01N33/6854 ,  A61K38/00 ,  C07K2317/41 ,  G01N2333/16 ,  G01N2333/4725

Abstract: The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

公开(公告)号：US20240329054A1

公开(公告)日：2024-10-03

申请号：US18656427

申请日：2024-05-06

Applicant: Alector LLC

Inventor： Robert PAUL ,  Michael F. WARD ,  Felix Leejia YEH ,  Yijie LIAO ,  Herve RHINN ,  Arnon ROSENTHAL

IPC: G01N33/68

CPC classification number: G01N33/6854 ,  G01N33/6896 ,  G01N2333/70503 ,  G01N2800/2821 ,  G01N2800/52

Abstract: The present disclosure relates generally to biomarkers of activity and/or therapeutic efficacy of anti-CD33 antibodies for the treatment of a disease or injury in an individual, as well as methods related thereto.

公开(公告)号：US12103972B2

公开(公告)日：2024-10-01

申请号：US17044493

申请日：2019-04-05

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： Gordon J. Freeman ,  Antonio R. Arulanandam

IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  G01N33/50 ,  G01N33/68

CPC classification number: C07K16/2827 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  G01N33/5011 ,  G01N33/6854 ,  A61K2039/505

Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies, and antigen-binding fragments thereof, that specifically bind to HHLA2, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.